NeuroOne’s Evo sEEG System. Credit: PRNewswire / NeuroOne Medical Technologies Corporation.

NeuroOne Medical Technologies (NeuroOne) has announced the first robotic neurosurgery case using its Evo sEEG electrode.

The procedure was conducted by Dr William Bingaman at Cleveland Clinic. It is claimed to be the first clinical case to use NeuroOne’s Evo sEEG electrode, available exclusively through Zimmer Biomet in the US.

Related Company Profiles

View all

The electrode was combined with Zimmer Biomet’s ROSA One Brain, a robotic platform designed to aid surgeons in the planning and execution of complex minimally invasive neurosurgical procedures.

NeuroOne CEO Dave Rosa said: “This clinical case utilising our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet.

“Now that Zimmer Biomet has commenced US distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet’s robotics platform which was the foundation of our interest to partner with Zimmer Biomet.”

The Evo sEEG electrode technology is used for stereoelectroencephalography (sEEG) recording and brain stimulation. It also has the potential to support future capabilities for spinal cord stimulation and the future development of ablation solutions for patients with conditions such as Parkinson’s disease, epilepsy and chronic back pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In October last year, NeuroOne secured 510(k) approval from the US Food and Drug Administration to commercialise its Evo sEEG electrode technology.

It is intended for temporary (less than 30 days) use with recording, monitoring and stimulation equipment to record, monitor and stimulate electrical signals at the subsurface level of the brain.

NeuroOne offers minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions.